Topotarget CEO: It actually saves us money
Biotech company Topotarget and commercial partner Spectrum Pharmaceuticals have announced a change in the commercialization plans for candidate drug Belinostat. Topotarget’s CEO calls it am ideal agreement.
by Benjamin Werner Christensen
An altered licensing agreement that now sees Spectrum assuming responsibility for both clinical and commercial production of candidate drug Belinostat for the treatment of peripheral T-cell lymphoma (PTCL) will save Topotarget a great deal of expenses going forward.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Positive data ease partner search
For abonnenter
